NCT03712813已完成不适用
Effect of Low Intensity Vibration (LIV) on Aromatase Inhibitor- Induced Musculoskeletal Dysfunction in Early Stage Breast Cancer Survivors
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 72
- 试验地点
- 1
- 主要终点
- Mean change in energetic capacity measured by peak power generation on a stationary bicycle
研究概览
简要总结
The purpose of this study is to compare the effect of low intensity vibration (LIV) delivered for 10 minutes twice daily for 12 months on skeletal muscle function, in terms of energetic capacity measured by power generation on a stationary bicycle, among patients with early stage breast cancer planned to initiate aromatase inhibitor therapy who do not currently participate in regular exercise, compared to a wait- listed control.
详细描述
This is a randomized phase II, two arm, single-center study designed to compare the effect of LIV versus wait-list control on the clinical parameter of energetic capacity, or power generation, in patients with early stage breast cancer receiving aromatase inhibitor therapy over a 12-month period. The primary endpoint is the 12-month change in energetic capacity since baseline.
Primary Objective To compare the effect of LIV delivered for 10 minutes twice daily for 12 months on skeletal muscle function, in terms of energetic capacity measured by power generation on a stationary bicycle, among patients with early stage breast cancer planned to initiate aromatase inhibitor therapy who do not currently participate in regular exercise, compared to a wait- listed control
Secondary Objectives
- To compare the effect of LIV versus wait-listed control upon muscle contractile properties including peak power, fatigue resistance, and recovery, measured by isokinetic knee extension
- To compare the effect of LIV versus wait- listed control upon body composition (lean mass, total adiposity) measured by DXA scan
- To compare the effect of LIV versus wait- listed control upon bone mineral density (T score) measured by DXA scan
- To compare the effect of LIV versus wait- listed control upon muscle adipose infiltration measured by muscle density on peripheral quantitative CT imaging of the proximal and distal tibia and radius
- To compare the effect of LIV versus wait-listed control on trabecular and cortical volumetric bone mineral density by high resolution peripheral quantitative CT of the distal and diaphyseal tibia and radius
- To compare the effect of LIV versus wait- listed control on serologic markers of bone turnover, including TGF-beta and NTX
- To compare the effect of LIV versus wait- listed controls upon patient reported outcome measures of fatigue (measured by the Basic Fatigue Inventory), muscle ache, and joint pain (measured by PRO-CTCAE)
- To describe the feasibility of LIV in this patient population, defined by patient compliance and follow up with the intervention
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Diagnosis of DCIS or stage I, II, or III breast cancer 3 Planned to initiate an AI
- •Post- menopausal defined as ≥ 60 years of age, prior bilateral oophorectomy, or age over 50 and absence of any menstrual periods in the last 12 months, or FSH and estradiol in the menopausal range
- •Premenopausal patients receiving chemical ovarian suppression are allowed
- •Prior aromatase inhibitor use (if this is a second primary, for example) is allowed as long as it has been more than 12 months
- •Prior tamoxifen is allowed if switching to an aromatase inhibitor, as long as it has been 28 days between last tamoxifen dose and the baseline procedures (per the half-life of tamoxifen)
- •4. Completion of all primary therapy for breast cancer, including surgery, radiation, and chemotherapy. Patients must be ≥ 21 days from chemotherapy completion and ≥14 days from radiation completion. Ongoing HER2 targeted therapy with trastuzumab or pertuzumab, or TDM1 is allowed. Ongoing therapy with abemaciclib per standard of care is allowed.
- •5. Baseline T score > - 2.5 on DXA
- •Body weight less than 275 lbs., as dictated by the weight limit for the LIV platforms
- •ECOG performance status of 0-2 at the time of study enrollment
- •Informed consent and authorization of the release of health information must be obtained according to institutional guidelines
- •Physically able to stand unassisted for 10 minutes at a time
- •Currently not participating in regular exercise (defined as less than 90 minutes of moderate to vigorous exercise per week measured by the RPAQ questionnaire)
排除标准
- •Unwilling to co-enroll onto the companion FIT core study (IRB study #1707550885)
- •Diagnosis of other disorder affecting bone function or turnover, such as Paget's disease, renal osteodystrophy, parathyroid disorders, vitamin D deficiency/osteomalacia, chronic renal disease (Cr > 1.4)
- •a. Vitamin D will be checked during screening. Patients with Vit D < 20 can be enrolled if supplementation is initiated per the treating physician.
- •Prior history of non-traumatic, fragility bone fracture
- •Any muscle or neuromuscular disorder affecting muscle function, such as muscular dystrophy, myositis, or amyotrophic lateral sclerosis
- •Use of bisphosphonates or denosumab within the prior 12 months
- •History of retinal detachment
- •Current or planned pacemaker
- •Current or planned cochlear implant
- •Any condition precluding power protocol participation (i.e. riding a stationary bicycle), including: NYHA class III or IV congestive heart failure, uncontrolled angina, myocardial infarction in the prior 12 months, orthopedic surgery in the previous 6 months or plans for orthopedic surgery during the study period, chronic uncontrolled pulmonary conditions such as uncontrolled asthma (symptoms > 2 days/week) or dyspnea requiring oxygen, symptomatic peripheral vascular disease, or any other comorbidity that would interfere with the ability to complete and comply with the protocol in the opinion of the investigator
- •Metastatic breast cancer
- •a. History of prior treated malignancies, other than breast cancer, that are now stable, are in remission, and do not require active therapy, are acceptable.
- •Patients requiring chronic anticoagulation are excluded from participation in the optional muscle biopsy collection.
研究组 & 干预措施
Wait-Listed Control
No Intervention
Macrodyne LivMD plate
Experimental
干预措施: Macrodyne LivMD plate (Device)
结局指标
主要结局
Mean change in energetic capacity measured by peak power generation on a stationary bicycle
时间窗: Baseline, 6 months, and 12 months
Peak power will be measured using the Power Protocol-B
次要结局
- Change in muscle contractile properties including peak power, fatigue resistance, and time to recovery measured by isokinetic knee extension(Baseline, 6 months, and 12 months)
- Change in trabecular and cortical volumetric bone mineral density(Baseline and 12 months)
- Change in bone mineral density of the lumbar spine by T score(Baseline, 6 months, and 12 months)
- Change in lean body mass(Baseline, 6 months, and 12 months)
- Change in serologic bone markers of bone turnover (TGF-beta and NTX) by quantitative measurements using ELISA(Baseline and 12 months)
- Patient reported aching muscles and joint pain measured by NCI Patient Reported Outcomes-Common Terminology Criteria for Adverse Events score(Baseline, 6 months, and 12 months)
- Patient reported fatigue measured by the Basic Fatigue Inventory score(Baseline, 6 months, and 12 months)
- Feasibility of low intensity vibration defined by patient compliance(Once monthly from Baseline to 12 months)
研究者
Tarah J Ballinger, MD
Assistant Professor of Clinical Medicine
Indiana University
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Vibration Training in Healthy IndividualsMuscle StrengthLower LimbExposure VibrationNCT04738916Okan University40
进行中（未招募）
不适用
Analysis of the effect of vibration in patients with strokeSequelae of stroke, Abnormality of gait and mobilityI69.4RBR-34v9pxniversidade do Vale do Sapucaí
已完成
不适用
Sensory Stimulation in FibromyalgiaFibromyalgiaNCT03227952Jesus Pujol77
已完成
不适用
"VIBES"--Low Magnitude Mechanical Stimulation to Improve Bone Mineral DensityOsteopeniaNCT00396994Hebrew SeniorLife174
已完成
不适用
Investigation of the Effects of Local Vibration Applied to Different Regions and Spinal Stabilization ExercisesAtaxiaMultiple SclerosisNCT05885282Hacettepe University30